DEPARTMENT OF CORRECTIONS

1990 ◽  
Vol 12 (1) ◽  
pp. 21-21
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Children And Adolescents ◽  
Glucose Concentration ◽  
Blood Concentration ◽  
Blood Glucose Concentration ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Insulin Dependent

In the article by Ginsberg-Fellner in the February 1990 issue of Pediatrics in Review, "Insulin-Dependent Diabetes Mellitus," the blood concentration at which the kidneys excrete glucose was stated incorrectly. On page 242, the 22nd line of the section on the management of children and adolescents with diabetes should indicate that this occurs only when the blood glucose concentration is greater than 180 mg/dL.

The effect of acute hyperglycemia on the plasma C-peptide response to intravenous glucagon or to a mixed meal in insulin-dependent diabetes mellitus

1991 ◽  
Vol 124 (5) ◽  
pp. 556-562 ◽  
Author(s):  
H. J. Gjessing ◽  
B. Reinholdt ◽  
O. K. Faber ◽  
O. Pedersen
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Glucose Concentration ◽  
Blood Glucose Concentration ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
C Peptide ◽  
Significant Difference ◽  
Insulin Dependent

Abstract. The dose-response relationships between prestimulatory blood glucose concentration and the plasma C-peptide responses to stimulation with 1 mg of glucagon iv or a standard mixed meal were studied in 8 C-peptide positive patients with insulin-dependent diabetes mellitus. Hyperglycemia was maintained for 90 min before stimulation using a hyperglycemic clamp technique. Each test was performed at the steady state blood glucose levels ~5, ~12, and ~20 mmol/l. The glucose potentiation of the incremental plasma C-peptide area under the curve at the two levels of hyperglycemia in percent of the area at normoglycemia (median and range) was 343% (53-1053) (p<0.05) and 341% (267-1027) (p<0.05) after glucagon and 140% (76-227) (NS) and 251% (95-1700) (p<0.05) after the meal. The corresponding relative glucose potentiation of plasma C-peptide 6 min after stimulation with glucagon was 124% (100-427) (p<0.02) and 144% (100-209) (p<0.05). There was no significant difference in the degree of glucose potentiation at ~12 or ~20 mmol/l. Furthermore, there was no significant difference in the degree of glucose potentiation of the different estimated values of B-cell function. In conclusion, the plasma C-peptide responses to iv glucagon or to a standard test meal were markedly potentiated by acute hyperglycemia in insulin-dependent diabetes mellitus. No further potentiation was, however, obtained when the prestimulatory blood glucose concentration was raised above 12 mmol/l. These findings contrast those reported in non-insulin-dependent diabetes, where endogenous insulin secretion is potentiated further when the blood glucose concentration is raised to ~20 mmol/l.

Erythrocyte Insulin Binding in Insulin-Dependent Diabetes Mellitus: Lack of Relationship to Duration and Control of Diabetes in Children and Adolescents

PEDIATRICS ◽  
1980 ◽  
Vol 66 (3) ◽  
pp. 385-390
Author(s):  
Michael S. Kappy ◽  
Leslie P. Plotnick ◽  
Joann C. Findlay ◽  
Richard D. Kayne
Keyword(s):  
Diabetes Mellitus ◽  
Children And Adolescents ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Binding ◽  
Diabetic Control ◽  
Insulin Dependent Diabetes ◽  
Liver Fat ◽  
Dependent Diabetes Mellitus ◽  
Control Of Diabetes ◽  
Insulin Dependent

Insulin binding was measured in the erythrocytes (RBCs) of four children and 12 adolescents with insulin-dependent diabetes mellitus in the basal (fasting, nonketotic) state. Children and adolescents with insulin-dependent diabetes mellitus showed normal binding of insulin to their RBCs when expressed as the total insulin bound over the physiologic range of insulin concentrations. The insulin receptor concentration and receptor binding affinity for insulin were also normal. These parameters of insulin binding were not correlated with either the duration of diabetes or the degree of diabetic control in the patients. Since insulin binding by erythrocytes has been shown to reflect binding by traditional target tissues (liver, fat), the data suggest that alterations in binding of insulin to cells in children and adolescents with insulin-dependent diabetes mellitus probably play little, if any, role in the response of these patients to exogenous insulin or in the control of their glucose metabolism in the basal state.

Oral hypoglycaemics for diabetes: when and which?

1991 ◽  
Vol 29 (4) ◽  
pp. 13-16
Keyword(s):  
Diabetes Mellitus ◽  
Blood Glucose ◽  
Insulin Dependent Diabetes Mellitus ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Regular Exercise ◽  
Control Blood Glucose ◽  
District Policy ◽  
Insulin Dependent ◽  
Market Leader

People with non-insulin-dependent diabetes mellitus should modify their diet, avoid obesity and take regular exercise. An oral hypoglycaemic drug may be needed if these measures fail to control blood glucose, but it is now clear that they commonly cause hypoglycaemia. More than 3 million prescriptions were issued in 1988 for the sulphonylureas (eight currently available) and the biguanide, metformin. Glibenclamide is the market leader (1.4 million prescriptions in 1988), followed by metformin (950,000), chlorpropamide (280,000), tolbutamide (260,000) and gliclazide (200,000). Instituting a district policy to restrict the choice of sulphonylureas can improve care and save money.1 No new oral hypoglycaemics have been marketed since we last reviewed them2 but their place in overall management has been clarified.

Insulin-dependent Diabetes Mellitus

1994 ◽  
Vol 15 (4) ◽  
pp. 137-148
Author(s):  
Leslie Plotnick
Keyword(s):  
Diabetes Mellitus ◽  
Children And Adolescents ◽  
Plasma Glucose ◽  
Behavioral Problems ◽  
Insulin Dependent Diabetes Mellitus ◽  
Health Care Team ◽  
Insulin Dependent Diabetes ◽  
Dependent Diabetes Mellitus ◽  
Type I ◽  
Insulin Dependent

Insulin-dependent diabetes mellitus (IDDM) is a chronic, serious disease in children and adolescents. Its diagnosis is straightforward and rarely subtle. The major challenges of this disease for the child, family, and health-care team involve long-term management of medical and metabolic factors as well as psychological and behavioral concerns. While developments in the past 10 to 15 years have made metabolic control technically possible, psychological stresses and behavioral problems often interfere with metabolic goals. There are few, if any, other diseases that require such intensive and extensive self-care skills. Definitions Diabetes generally is classified in two types. Type I, or IDDM, is seen mostly in younger people (children and adolescents). It previously was called juvenile onset or ketosisprone. Insulin deficiency characterizes IDDM, and patients need exogenous insulin for survival. Type II, or non-IDDM (NIDDM), previously called adult or maturity onset, is the type seen most commonly in older people and in obesity and is not discussed in this review. To make a diagnosis of diabetes, a child must have either classic symptoms with a random plasma glucose above 200 mg/dL or specific plasma glucose levels before and after a standard glucose load if asymptomatic. The diagnosis of IDDM usually is clear-cut.

Sign in / Sign up

Export Citation Format

Share Document